Understanding the sensitized patient.
New technologies have resulted in the ability to identify the presence of IgG human leukocyte antigen (HLA) or non-HLA antibodies in the sera of potential solid organ transplant recipients. Knowledge of the presence of these antibodies, their antigen specificities, and strength (titer) is crucial to understanding a patient's state of immunologic sensitization and reactivity. Finally, these data, when correlated with sensitive crossmatch results, allow clinicians to make more knowledgeable clinical decisions when paring donors and recipients for transplant.
Kerman
Ronald H
RH
The University of Texas Medical School, Houston, TX 77030, USA. ronald.h.kerman@uth.tmc.edu
D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D001788:Blood Grouping and Crossmatching; D000075202:Contraindications; D003601:Cytotoxicity Tests, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006084:Graft Rejection / Q000175:diagnosis / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D016040:Lung Transplantation / Q000276:immunology; D016377:Organ Transplantation; D013601:T-Lymphocytes / Q000276:immunology; D014181:Transplantation Immunology